Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments ; volume:13 ; number:1 ; day:28 ; month:3 ; year:2013 ; pages:1-10 ; date:12.2013
BMC cancer ; 13, Heft 1 (28.3.2013), 1-10, 12.2013
- Creator
-
Del Mastro, Lucia
- Contributor
-
Fabi, Alessandra
Mansutti, Mauro
De Laurentiis, Michele
Durando, Antonio
Merlo, Domenico Franco
Bruzzi, Paolo
La Torre, Ignazia
Ceccarelli, Matteo
Kazeem, Gbenga
Marchi, Paolo
Boy, Davide
Venturini, Marco
De Placido, Sabino
Cognetti, Francesco
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-13-164
- URN
-
urn:nbn:de:1111-201603049995
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Del Mastro, Lucia
- Fabi, Alessandra
- Mansutti, Mauro
- De Laurentiis, Michele
- Durando, Antonio
- Merlo, Domenico Franco
- Bruzzi, Paolo
- La Torre, Ignazia
- Ceccarelli, Matteo
- Kazeem, Gbenga
- Marchi, Paolo
- Boy, Davide
- Venturini, Marco
- De Placido, Sabino
- Cognetti, Francesco
- SpringerLink (Online service)
Other Objects (12)
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Pharmakokinetik der Taxane : (Paclitaxel und Docetaxel)
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
School choice with hybrid schedules
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Pharmakokinetik der Taxane : (Paclitaxel und Docetaxel)
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
School choice with hybrid schedules
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Pharmakokinetik der Taxane : (Paclitaxel und Docetaxel)
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
School choice with hybrid schedules
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)